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ABSTRACT
INTRODUCTION: Obstructive sleep apnea syndrome (OSAS) is commonly associated with obesity, insulin 
resistance, metabolic syndrome, hypertension, and coronary artery disease. Irisin is a newly identified 
myokine and its serum concentration was found to be correlated with cardiac troponin and creatin kinase-
MB in acute myocardial infarction patients. Furthermore, irisin levels were positively associated with 
endothelium-dependent vasodilation in type 2 diabetic patients.
AIM: In this study, we aimed to investigate serum irisin level in the newly diagnosed OSAS patients.
MATERIALS AND METHODS: After obtaining ethical approval, 32 OSAS patients were included. All 
patients gave written informed consent. Diagnosis of OSAS was verified by an overnight polysomnography 
(PSG) and made by an apnea hypopnea index equal to or higher than 5. Venous blood samples were collected 
in the morning between 08.00 – 10.00 after PSG (n=25) or after one-night CPAP treatment (n=7). Serum 
irisin concentrations were studied by ELISA.
RESULTS AND CONCLUSION: Serum irisin concentrations were significantly higher in newly 
diagnosed OSAS group than in OSAS group after one night of CPAP treatment (199.7±42.4 vs 159.7±18.3 
ng/mL respectively; p<0.01). These results suggest that increased serum irisin levels can be reduced by 
CPAP treatment and elevated serum irisin levels may be due to increased respiratory muscle activity 
and body temperature.
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INTRODUCTION
Obstructive sleep apnea syndrome (OSAS) is a 
prevalent systemic disease characterized by repeti-
tive episodes of breathing pauses due to upper air-
way obstruction during sleep (1). Prevalence of OSAS 
in population-based studies varies between 3% to 
7% and 2% to 5% in adult men and women, respec-
tively (2). OSAS is commonly associated with obe-
sity, insulin resistance, metabolic syndrome, hy-
pertension, coronary artery disease and myocardi-
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MATERIALS AND METHODS
Study Group
The study protocol was approved by local eth-
ics committee and all procedures performed were 
in accordance with the ethical standards of the in-
stitutional and/or national research regulations. The 
study population consisted of 32 patients with OSAS 
(mean age, 47.7±12.6 year). Diagnosis of OSAS was 
verified by whole night computerized polysomnog-
raphy. Body mass index (BMI) was calculated as 
body weight in kilograms divided by the square of 
height in meters. All of the patients had complaints 
of snoring, witnessed apnea, daytime sleepiness, and 
frequent night awakenings. An apnea hypopnea in-
dex (AHI) higher than 5 was accepted as the diag-
nostic marker of OSAS. Fasting blood samples were 
obtained in the morning after the sleep study.
Polysomnography
Full-night polysomnography (PSG) was per-
formed by a computerized system (Compumed-
ics 44E Series, Compumedics Australia) and a soft-
ware (Profusion PSG2, Compumedics, Australia). 
Twenty-channel polysomnography included electro-
encephalography (F3A2, F4A1, C4A2, C3A1, O2A1, 
O1A2), left and right ocular movements, submental 
electromyography, a nasal cannula to record nasal 
pressure and a thermistor to monitor oronasal air-
flow, respiratory effort by thoraco-abdominal belts, 
finger pulse oximetry, a neck microphone to record 
snoring, left and right anterior tibialis movement 
sensors, electrocardiography and body posture. PSG 
recordings were continued for at least 6 hours. Apnea 
was defined as a complete cessation of airflow last-
ing for at least 10 seconds. Hypopnea was defined as 
a decrease in airflow, if it was associated with either 
arousal (defined as the appearance for 3 seconds of 
an alpha rhythm on EEG channels or an increase in 
the submental EMG signal) or oxygen desaturation 
of at least 3%. AHI was calculated by dividing the to-
tal number of apnea and hypopnea events by the to-
tal sleep time. The minimal oxygen saturation was 
determined as the lowest saturation value associated 
with a respiratory event.
CPAP Treatment
Overnight continuous positive airway pres-
sure was applied in automatic titration mode under 
PSG in the sleep laboratory (S8 Autoset SpiritTM II, 
al infarction (3). Although the cardiovascular conse-
quences of OSAS represent the biggest health burden 
of the disease, the mechanisms which link obstruc-
tive sleep apnea (OSA) to cardiovascular disorders 
have not been completely understood. Current body 
of knowledge suggests that oxidative stress and sys-
temic inflammation mediate endothelial dysfunc-
tion and eventually development of cardiovascular 
disease in OSAS (3). Adipocyte dysfunction and al-
tered adipokine secretion profile (including leptin 
increase and adiponectin decrease) may also contrib-
ute to the association of OSAS and heart disease (4). 
Recently, we demonstrated higher arginase activity 
and lower nitric oxide levels in patients with OSAS 
than in healthy controls (5). Furthermore, arginase 
activity was correlated with the presence of cardio-
vascular disease in patients with OSAS (5). Anoth-
er potential candidate responsible for the endothelial 
dysfunction and development of cardiovascular dis-
ease in OSAS is irisin.
Irisin is a newly identified myokine secret-
ed from muscle tissue and its serum concentration 
was found to be correlated with cardiac troponin 
and creatin kinase-MB in acute myocardial infarc-
tion patients (6). Several recent studies demonstrated 
an association between irisin and endothelial func-
tion (7-9). Lower levels of irisin were found to be in-
dependently associated with endothelial dysfunction 
in non-hypertensive, non-diabetic obese subjects 
(9). Circulating irisin levels were positively associat-
ed with endothelium-dependent arterial dilation in 
type 2 diabetic patients (7). Furthermore, irisin had 
protective effects on endothelium and improved en-
dothelial function in an animal model of type 2 di-
abetes (8). These data collectively suggest that irisin 
may have a role in the pathogenesis of endothelial 
dysfunction and development of cardiovascular dis-
orders in patients with obstructive sleep apnea syn-
drome. However, there are only limited data on cir-
culating irisin levels in OSAS patients.
AIM
In this preliminary study, we investigated cir-
culating irisin levels in the newly diagnosed OSAS 
patients. Furthermore, we assessed the effects of one-
night CPAP treatment on serum irisin levels.
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ResMed, Australia). Auto-titrating mode automati-
cally adjusts pressure in response to snore, flow lim-
itation and obstructive sleep apneas. All patients 
used a nasal mask. Minimum and maximum pres-
sure limits were set at 4 cmH2O and 20 cmH2O, re-
spectively. Seven patients underwent one-night pos-
itive airway pressure treatment during polysomno-
graphic recording.
Blood Sampling
Peripheral venous blood samples were obtained 
in the morning after the diagnostic study night or af-
ter one night of CPAP treatment. The blood samples, 
centrifuged at 4,000 x g for 10 min, and serum sam-
ples were aliquoted and stored at -20°C for analysis.
Biochemical Measurements
Serum irisin measurements were performed 
by enzyme linked immunosorbent assay (ELISA). 
Commercial kit (Irisin Competitive ELISA Kit, Cat. 
No. AG-45A-0046EK-KI01, Adipogen, Switzerland) 
was used for irisin measurement based on leaflet in-
box instructions. Intra-and inter-assay coefficient of 
variation were <8% and <10%, respectively. Sample 
absorbance of ELISA reader was set at 450 nm.
Statistical Analysis
All data were given as means and standard de-
viations unless otherwise indicated. Normal distri-
bution of variables was tested by One Sample Kol-
mogorov Smirnov test. Comparison of mean values 
obtained pre- and post-exercise measurements were 
performed by paired samples t-test for parametric 
variables, and Wilcoxon signed ranks test for non-
parametric variables. Between group comparisons 
were made by t-test for parametric variables and by 
Mann Whitney U test for non-parametric variables. 
The analysis of covariance test was used to test the 
difference between the mean percent changes in both 
gender groups. A p value lower than 0.05 was accept-
ed as statistically significant.
RESULTS
General characteristics of the OSAS and CPAP 
groups are given in Table 1. OSAS and CPAP groups 
were comparable in terms of age, weight, height and 
body mass index. Male-to-female ratio was 6/1 and 
17/8 in CPAP and OSAS groups respectively. There 
was no significant gender difference between the 
two groups (Chi-Square p>0.05). Polysomnography 
showed that apnea hypopnea index was significant-
ly lower and minimum oxygen saturation was signif-
icantly higher in CPAP group than in OSAS group 
(Table 1). All patients in CPAP group had moderate-
to-severe OSAS based on apnea hypopnea index. The 
mean apnea-hypopnea index reduced from 50.7±27.3 





Age, yr 45.8±11.6 51.1±13.3
Height, m 1.68±0.09 1.69±0.07
Weight, kg 94.0±23.2 90.1±12.3
BMI, kg/m2 33.0±7.8 31.7±5.8
AHI, hour-1 34.2±30.7 3.3±7.2***
MinO2, % 80.9±10.1 91.1±6.0**
REM, % 17.2±7.7 16.4±5.5
N1, % 5.6±5.3 4.0±3.2
N2, % 54.8±17.0 41.2±12.3*
N3, % 22.3±12.8 38.3±11.0**
Irisin, ng/mL 199.7±42.4 159.7±18.3**
Abbreviations: OSAS, obstructive sleep apnea syndrome; 
CPAP, continuous positive airway pressure; BMI, body mass 
index; AHI, apnea hypopnea index; REM, rapid eye move-
ment; N1, stage 1 NREM sleep; N2, stage 2 NREM sleep; N3, 
stage 3 NREM sleep.
*p<0.05; **p<0.01; ***p<0.001 (Mann-Whitney U test)
Table 1. General characteristics, polysomnography and 
serum irisin results of obstructive sleep apnea and contin-
uous positive airway pressure (CPAP) patients
Fig. 1. Comparison of serum irisin concentrations of pa-
tients with obstructive sleep apnea syndrome (OSAS) and 
OSAS patients after one night of continuous positive air-
way pressure (CPAP) treatment
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mean serum irisin level was significantly higher in 
OSAS group (Fig. 1).
DISCUSSION
The main finding of this study is that there are 
higher serum irisin levels in newly diagnosed OSAS 
patients than OSAS patients with one night of CPAP 
treatment. There may be several possible explanations 
for higher irisin levels in OSAS. One explanation is 
the increased inspiratory effort in patients with sleep 
disordered breathing (10). Obstructive events during 
sleep resume with an increase in respiratory muscle 
activity. As irisin is secreted from muscles, increased 
activity of respiratory muscles during nocturnal ob-
structive events in these patients may contribute to 
elevated serum irisin levels. Unfortunately, no previ-
ous study correlated irisin alterations to respiratory 
effort in OSAS patients. Another explanation is body 
temperature-induced irisin secretion. Both serum 
and saliva irisin concentrations have been shown to 
increase after a 45-minute Turkish bath with an am-
bient temperature of 47±3°C (11). Patients with OSAS 
commonly report nocturnal sweating and hyperhy-
drosis which may be a surrogate marker of increased 
body temperature. On the contrary, some other stud-
ies suggested irisin as a cold-activated thermogenic 
factor (12). In fact, cold exposure is known to drive 
browning of white adipose tissue (13) which is the 
original function of irisin (14). In addition, we have 
already known that nocturnal hypoxia may influ-
ence adaptive thermogenesis in apneic patients (15). 
Thus, alterations in circulating irisin concentration 
of OSAS patients would be related to the regulation 
of body temperature in these patients.
Li et al. (16) reported decreased serum irisin 
concentrations in patients with OSAS. They suggest-
ed that irisin may be involved in the mechanism of 
OSAS development and progression through its an-
ti-inflammatory effects (16), which means first irisin 
levels decrease and then OSAS develops. On the con-
trary, we found elevated serum irisin levels in OSAS 
which reduced after one night of CPAP treatment. 
Our findings suggested that altered circulating irisin 
level was a result rather than a cause in OSAS.
Elevated serum irisin levels may have some 
pathophysiologic and clinical implications. In-
creased irisin levels were found to be in positive cor-
relation with insulin resistance (17, 18) and metabolic 
syndrome independent from obesity (17). They were 
also associated with vascular atherosclerosis in non-
diabetic adult subjects (18). Previous studies showed 
an association between OSAS and high frequency of 
glucose metabolism disorders and insulin resistance 
(19). Furthermore, 8 weeks of CPAP treatment in-
creased insulin secretion capacity in patients with 
moderate-to-severe OSAS (20). These studies suggest 
that elevated irisin levels may, at least in part, have 
a role in development of metabolic syndrome, insu-
lin resistance, and atherosclerosis in OSAS. Curious-
ly, irisin has some potential to be a marker of meta-
bolic disorder in patients with sleep apnea.
This study has several limitations. First, a con-
trol group without OSAS is lacking. Adding such 
group would enable us to compare between OSAS 
and control subjects. Second, we did not evaluate the 
cardiovascular comorbidities in this patient group. 
Analysis of such subsets would increase the level of 
difference in irisin concentrations. And finally, the 
exercise history of these patients was not evaluated. 
Regular exercise versus sedentary lifestyle may show 
differential impact on irisin levels.
CONCLUSION
Here for the first time, we report elevated serum 
irisin levels in patients with OSAS which reduced fol-
lowing a night under CPAP treatment. Elevated se-
rum irisin levels may be due to increased respiratory 
muscle activity and body temperature.
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